Table 1.
Major pathology criteria of the eligible patients (n = 1226)
| Major pathologic criteria | NL patients (n = 368) |
UK patients (n = 858) |
|||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Age | <60 | 100 | 37% | 239 | 28% |
| 60–69 | 110 | 41% | 373 | 44% | |
| ≥70 | 58 | 22% | 243 | 28% | |
| Missing | 100 | 3 | |||
| FIGO stage (2009) | IA | 72 | 20% | 138 | 16% |
| IB | 93 | 26% | 178 | 21% | |
| II | 99 | 27% | 263 | 31% | |
| IIIA | 43 | 12% | 97 | 12% | |
| IIIB | 18 | 5% | 62 | 7% | |
| IIIC | 40 | 11% | 101 | 12% | |
| Missing | 3 | 19 | |||
| Histological type | Endometrioid or mucinous | 262 | 71% | 501 | 59% |
| Serous or mixed serous | 66 | 18% | 193 | 23% | |
| Clear cell or mixed clear cell | 31 | 8% | 111 | 13% | |
| Othera | 9 | 2% | 45 | 5% | |
| Missing | 0 | 8 | |||
| Histological grade | 1 | 81 | 22% | 155 | 18% |
| 2 | 53 | 14% | 135 | 16% | |
| 3 | 127 | 35% | 201 | 24% | |
| NEEC | 107 | 29% | 354 | 42% | |
| Missing | 0 | 13 | |||
| Myometrial invasion | <50% | 135 | 37% | 215 | 38% |
| ≥50% | 233 | 63% | 346 | 62% | |
| Missing | 0 | 297 | |||
| Growth through serosa | Yes | 21 | 6% | 31 | 4% |
| No | 346 | 94% | 675 | 96% | |
| Missing | 1 | 152 | |||
| Cervical glandular involvement | Yes | 135 | 38% | 172 | 43% |
| No | 224 | 62% | 230 | 57% | |
| Missing | 9 | 456 | |||
| Cervical stromal involvement | Yes | 138 | 38% | 339 | 47% |
| No | 225 | 62% | 382 | 53% | |
| Missing | 5 | 137 | |||
| LVSI | Yes | 198 | 54% | 287 | 60% |
| No | 169 | 46% | 194 | 40% | |
| Missing | 1 | 377 | |||
| Involvement of the ovaries | Yes | 46 | 13% | 67 | 9% |
| No | 322 | 87% | 666 | 91% | |
| Missing | 0 | 125 | |||
| Lymph node involvement | Not applicable | 252 | 69% | 553 | 66% |
| No malignancy | 73 | 20% | 184 | 22% | |
| Metastasis | 41 | 11% | 101 | 12% | |
| Missing | 2 | 20 | |||
| Parametrial involvement | Yes | 24 | 13% | 61 | 16% |
| No | 167 | 87% | 326 | 84% | |
| Missing | 177 | 471 | |||
Missing values were not taken into account to the percentages.
The pathology criteria of the NL versus the UK patients were based on review pathology.
a
Other histology includes undifferentiated, carcinosarcoma or mixed combinations other than serous/clear cell with endometrioid.
FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymph-vascular space invasion; EEC, endometrioid endometrial cancer; NEEC, non-endometrioid endometrial cancer.